Eisai Inc. Announces Non-Exclusive Licensing Agreement with Generic Drug Manufacturer to Provide Generic Version of donepezil HCl 23 mg PR Newswire WOODCLIFF LAKE, N.J., Aug. 29, 2013 WOODCLIFF LAKE, N.J., Aug. 29, 2013 /PRNewswire/ --Eisai Inc. announced that the company has recently entered into a non-exclusive licensing agreement in the United States with a manufacturer of generic pharmaceuticals that grants certain rights, including the right to market and offer for sale a generic version of donepezil hydrochloride 23 mg and a non-exclusive license to Eisai Intellectual Property covering donepezil hydrochloride 23 mg, including U.S. Patent No. 8,481,565. This agreement applies to the United States only. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO) About Eisai Inc. At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders).To learn more about Eisai Inc., please visit us at www.eisai.com/US. Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs. Media Inquiries Investor Inquiries Marcia Diljak Alex Scott Eisai Inc. Eisai Inc. (201) 746-2236 (201) 746-2177 SOURCE Eisai Inc. Website: http://www.eisai.com
Eisai Inc. Announces Non-Exclusive Licensing Agreement with Generic Drug Manufacturer to Provide Generic Version of donepezil
Press spacebar to pause and continue. Press esc to stop.